Table 4.

Overview of clinical studies with STNM01.

Study drug	Study	Phase	Study population	Study design	Cohort size	Drug dosage and frequency of doses	Primary endpoint	Results
STNM01	Phase 1 clinical study of siRNA targeting carbohydrate sulfotransferase 15 in Crohn's disease patients with active mucosal lesions (Suzuki et al., 2017)	Phase 1	CD patients with active endoscopic disease (SES-CD: from 1 to 11)	Double-blind, placebo-controlled study	18 CD patients	The patients were randomized to four different treatment arms: STNM01 at a dosage of 2.5 nM, STNM01 at a dosage of 25 nM, STNM01 at a dosage of 250 nM or placebo arm. The drug was administered endoscopically with a single dose submucosal injection	To evaluate the safety of STNM01	The study evidenced the safety of the drug and reduced the segmental SES-CD score

SES-CD, Simple Endoscopic Score for Crohn's disease; siRNA, silenceRNA; CD, Crohn's disease.